Literature DB >> 9259086

Pathology of transitional cell carcinoma of the bladder and its clinical implications.

R L Lapham1, J Y Ro, G A Staerkel, A G Ayala.   

Abstract

Transitional cell carcinomas are divided into superficial and muscle-invasive tumors. Most of them are superficial tumors, and approximately 15-20% are muscle-invasive carcinomas. Pathologists play a significant role in diagnosing bladder tumors and in reporting features important for determining prognosis. We will review the cytologic and histopathologic features that help determine prognosis, including depth of invasion, tumor grade, multicentricity, tumor size, and the presence of vascular/lymphatic invasion, blood group antigen expression, proliferative indices, and molecular markers. Brief mention will be made of specimen handling, interpretation, reporting, and histologic variants of transitional cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9259086     DOI: 10.1002/(sici)1098-2388(199709/10)13:5<307::aid-ssu4>3.0.co;2-h

Source DB:  PubMed          Journal:  Semin Surg Oncol        ISSN: 1098-2388


  9 in total

Review 1.  Expectant Management of Low-Risk Bladder Cancer.

Authors:  Zachary L Smith; Mark S Soloway
Journal:  Curr Urol Rep       Date:  2015-12       Impact factor: 3.092

2.  Plasma human neutrophil proteins-1, -2, and -3 levels in patients with bladder cancer.

Authors:  Mustafa Gunes; Ilhan Gecit; Necip Pirincci; Ahu Sarbay Kemik; Sevim Purisa; Kadir Ceylan; Mehmet Aslan
Journal:  J Cancer Res Clin Oncol       Date:  2012-09-26       Impact factor: 4.553

3.  Highly invasive transitional cell carcinoma of the bladder in a simian virus 40 T-antigen transgenic mouse model.

Authors:  P J Grippo; E P Sandgren
Journal:  Am J Pathol       Date:  2000-09       Impact factor: 4.307

4.  Inhibition of bladder cancer development by allyl isothiocyanate.

Authors:  Arup Bhattacharya; Li Tang; Yun Li; Feng Geng; Joseph D Paonessa; Shang Chiung Chen; Michael K K Wong; Yuesheng Zhang
Journal:  Carcinogenesis       Date:  2009-12-02       Impact factor: 4.944

5.  The association between CD2+ peripheral blood lymphocyte subsets and the relapse of bladder cancer in prophylactically BCG-treated patients.

Authors:  E Reyes; J Carballido; L Manzano; L Moltó; C Olivier; M Alvarez-Mon
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

6.  Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy.

Authors:  Miso Kim; Ja Hyeon Ku; Cheol Kwak; Hyeon Hoe Kim; Eunsik Lee; Bhumsuk Keam; Tae Min Kim; Dae Seog Heo; Se-Hoon Lee; Kyung Chul Moon
Journal:  PLoS One       Date:  2015-07-22       Impact factor: 3.240

7.  Expression of histone deacetylases 1, 2 and 3 in urothelial bladder cancer.

Authors:  Cédric Poyet; Bastian Jentsch; Thomas Hermanns; Daniel Schweckendiek; Hans-Helge Seifert; Martin Schmidtpeter; Tullio Sulser; Holger Moch; Peter J Wild; Glen Kristiansen
Journal:  BMC Clin Pathol       Date:  2014-03-13

8.  CD73 Predicts Favorable Prognosis in Patients with Nonmuscle-Invasive Urothelial Bladder Cancer.

Authors:  Marian S Wettstein; Lorenz Buser; Thomas Hermanns; Filip Roudnicky; Daniel Eberli; Philipp Baumeister; Tullio Sulser; Peter Wild; Cédric Poyet
Journal:  Dis Markers       Date:  2015-10-12       Impact factor: 3.434

9.  Connexin 43 expression predicts poor progression-free survival in patients with non-muscle invasive urothelial bladder cancer.

Authors:  Cédric Poyet; Lorenz Buser; Filip Roudnicky; Michael Detmar; Thomas Hermanns; Doris Mannhard; Andrej Höhn; Jan Rüschoff; Qing Zhong; Tullio Sulser; Holger Moch; Peter J Wild
Journal:  J Clin Pathol       Date:  2015-08-06       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.